ATE483711T1 - Spiroindolinonderivate - Google Patents

Spiroindolinonderivate

Info

Publication number
ATE483711T1
ATE483711T1 AT07712430T AT07712430T ATE483711T1 AT E483711 T1 ATE483711 T1 AT E483711T1 AT 07712430 T AT07712430 T AT 07712430T AT 07712430 T AT07712430 T AT 07712430T AT E483711 T1 ATE483711 T1 AT E483711T1
Authority
AT
Austria
Prior art keywords
spiroindolinone derivatives
spiroindolinone
derivatives
Prior art date
Application number
AT07712430T
Other languages
English (en)
Inventor
Li Chen
Qingjie Ding
Jin-Jun Liu
Song Yang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE483711T1 publication Critical patent/ATE483711T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07712430T 2006-03-13 2007-03-05 Spiroindolinonderivate ATE483711T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78195806P 2006-03-13 2006-03-13
US88175607P 2007-01-22 2007-01-22
PCT/EP2007/052038 WO2007104664A1 (en) 2006-03-13 2007-03-05 Spiroindolinone derivatives

Publications (1)

Publication Number Publication Date
ATE483711T1 true ATE483711T1 (de) 2010-10-15

Family

ID=38179455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07712430T ATE483711T1 (de) 2006-03-13 2007-03-05 Spiroindolinonderivate

Country Status (15)

Country Link
US (1) US20070213341A1 (de)
EP (1) EP1996590B1 (de)
JP (1) JP5038337B2 (de)
KR (1) KR101131031B1 (de)
AR (1) AR059957A1 (de)
AT (1) ATE483711T1 (de)
AU (1) AU2007224505B2 (de)
BR (1) BRPI0709605A2 (de)
CA (1) CA2645062A1 (de)
DE (1) DE602007009650D1 (de)
IL (1) IL193641A0 (de)
NO (1) NO20083726L (de)
RU (1) RU2435771C2 (de)
TW (1) TW200801000A (de)
WO (1) WO2007104664A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US8134001B2 (en) * 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2108641A1 (de) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren
EP2113503A1 (de) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren
KR100915320B1 (ko) 2008-09-29 2009-09-03 (주)메디룬 생리통완화를 위한 휴대용 조합자극기
US20100190814A1 (en) 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) * 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
EP2459570B1 (de) 2009-07-31 2014-12-24 Global Alliance For Tb Drug Development Nitroimidazooxazinanaloga und ihre verwendung
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9962459B2 (en) * 2010-07-02 2018-05-08 Basf Se Ultrathin fluid-absorbent cores
DK2684880T3 (en) * 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
EP2935263B1 (de) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituierte imidazopyridine als hdm2 inhibitoren
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MA53572A1 (fr) 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
ES2739697T3 (es) 2014-08-21 2020-02-03 Boehringer Ingelheim Int Nuevos compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53
EP3260119B1 (de) 2015-02-20 2023-11-15 Daiichi Sankyo Company, Limited Kombinationsverfahren zur behandlung von krebs
US10485794B2 (en) 2015-04-13 2019-11-26 Daiichi Sankyo Company, Limited Treatment method by combined use of MDM2 inhibitor and BTK inhibitor
HRP20210960T1 (hr) 2015-10-09 2021-09-03 Boehringer Ingelheim International Gmbh Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3527226A4 (de) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited Kombinationstherapieverfahren mit mdm2-inhibitor und dna-methyltransferase-inhibitor
EP3511334A1 (de) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indol-3,1'-pyrrolo[3,4-c]pyrrol] -2,3'-dion-verbindungen als therapeutische mittel, die tp53 aktivieren
US12296129B2 (en) 2018-03-07 2025-05-13 Soovu Labs, Inc. Systems and methods for improved pain relief from stimulation of thermal fibers
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
TR200200118T2 (tr) * 1999-07-21 2002-12-23 Astrazeneca Ab Yeni bileşimler
CA2644758A1 (en) * 2006-03-13 2007-09-20 F. Hoffmann-La Roche Ag Spiroindolinone derivatives

Also Published As

Publication number Publication date
JP2009529566A (ja) 2009-08-20
AR059957A1 (es) 2008-05-14
NO20083726L (no) 2008-11-25
EP1996590A1 (de) 2008-12-03
RU2008140386A (ru) 2010-04-20
DE602007009650D1 (de) 2010-11-18
BRPI0709605A2 (pt) 2011-07-19
WO2007104664A1 (en) 2007-09-20
US20070213341A1 (en) 2007-09-13
AU2007224505A1 (en) 2007-09-20
CA2645062A1 (en) 2007-09-20
KR20080095279A (ko) 2008-10-28
KR101131031B1 (ko) 2012-04-12
EP1996590B1 (de) 2010-10-06
AU2007224505B2 (en) 2012-05-03
IL193641A0 (en) 2009-05-04
JP5038337B2 (ja) 2012-10-03
TW200801000A (en) 2008-01-01
RU2435771C2 (ru) 2011-12-10

Similar Documents

Publication Publication Date Title
NL301266I2 (nl) Velagliflozine
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DE602006019782D1 (de) Kapselperforationsmodul
DE602007009650D1 (de) Spiroindolinonderivate
AT504580A3 (de) Scan-einrichtung
BRPI0813836A2 (pt) Derivados pirazólicos
DE602007000258D1 (de) Kassetteneinspannmechanismus
ATE518837T1 (de) Indazolamidderivate
EP2072519A4 (de) Diarylketiminderivat
DE502007001629D1 (de) Rfahren
DE602006020192D1 (de) Riemenscheibenanorndung
ATE546437T1 (de) Aminomethyl-4-imidazole
DK2152370T3 (da) Aryletherpyridazinonderivater
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
DE502007000361D1 (de) Stanznieteinheit
ATE519760T1 (de) Isoxazolimidazolderivate
DE602006019150D1 (de) Riemenscheibenanorndung
DE112007003147A5 (de) Rohr-Biegevorrichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1996590

Country of ref document: EP